


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Elazar Rabbani et al
Serial No. 08/978,637
Filed: November 25, 1997
Title: **NOVEL PROPERTY EFFECTING
AND/OR PROPERTY EXHIBITING
COMPOSITIONS FOR THERAPEUTIC
AND DIAGNOSTIC USE**



Group Art Unit: 1635

Ex'r: Andrew Wang

527 Madison Avenue, 9th Floor
New York, New York 10022
October 26, 1998

FILED BY EXPRESS MAIL

Honorable Commissioner
of Patents and Trademarks
Washington, D.C. 20231

Attention: **Box Sequence**

**COMMUNICATION DIRECTED TO NOTICE
TO COMPLY WITH SEQUENCE RULES**



Dear Sirs:

This Communication is directed to the Notice To Comply With Sequence Rules that was attached to the Notice to File Missing Parts of Application – Filing Date Granted that was mailed on April 24, 1998 in connection with the above-identified application.

In response to the sequence notice, Applicants hereby submit the following documents or items:

1. A Request For An Extension Of Time (Five Months) Under 37 C.F.R. §1.136(a);
2. A copy of the Notice To Comply With Requirements For Patent Application Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures Under 37 C.F.R. §§1.821 -1.825;

ENZ-53(D5)

EXPRESS MAIL CERTIFICATE	
"Express Mail" Label No	EM366566219
Deposit Date	OCTOBER 26, 1998
I hereby certify that this paper and the attachments herein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington DC 20231.	
 Ronald C. Fedus Reg. No. 32,567	 Date

Elazar Rabbani et al.

Serial No. 08/978,637

Filed: November 25, 1997

Page 2 (Communication Directed to Notice to Comply With Sequence Rules -
October 26, 1998)

3. initial paper copy of the "Sequence Listing;"
4. Amendment directing entry of the "Sequence Listing into the specification;
5. computer readable form (CFR) copy of the "Sequence Listing;" and
6. Declaration Under 37 C.F.R. §1.821(g) attesting that the content of the paper and computer readable copies are the same and include no new matter.

No fee is believed due in connection with this Communication or the documents or items submitted herewith other than the fee payment authorized in the Request For an Extension Of time (Five Months) Under 37 C.F.R. §1.136(a). If any other fee or fees are due, however, the Patent and Trademark Office is hereby authorized to charge the amount of any such fee to Deposit Account 05-1135, or to credit any overpayment thereto.

If helpful to processing this Communication, the undersigned may be contacted by telephone at (212) 583-0100 during the daytime hours.

Respectfully submitted,



Ronald C. Fedus
Registration No. 32,567
Attorney for Applicants

ENZO THERAPEUTICS, INC.
c/o Enzo Biochem, Inc.
527 Madison Avenue (9th Fl.)
New York, New York 10022
(212) 583-0100



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
---------------	-------------	-----------------------	---------------------

08/978,637 11/25/97 RABBANI

HM11/0424

RONALD C FEDUS
ENZO DIAGNOSTICS INC
ENZO BIOCHEM INC
1527 MADISON AVENUE 9TH FLOOR
NEW YORK NY 10022

E	ENZ-55 (DIV 5)
EXAMINER	

ART UNITING LA	PAPER NUMBER
----------------	--------------

4

1635
DATE MAILED:

04/24/98

APR 2 1998

Please find below a communication from the EXAMINER in charge of this application.

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

The specification and drawings disclose sequences which are not in compliance with the sequence rules.

Applicant is given THIRTY DAYS from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Andrew Wang whose telephone number is (703) 306-3217.

JOHN L. LeGUYADER
PRIMARY EXAMINER
GROUP 1800
1600